Figure 1.

Patient‐specific covariates (A) weight, (B) age, (C) prior anti‐TNFα therapy, (D) serum albumin and (E) faecal calprotectin, stratified by quartiles from low (quartile 1) to high (quartile 4) for estimated concentration and estimated clearance of vedolizumab at week 6 and at steady state. The relationship between patient‐specific covariates and estimated vedolizumab clearance and vedolizumab concentrations was expressed as P values for the monotonic trend analysis (A, B, D, E). P values for prior anti‐TNFα therapy were determined using the exact Cochran‐Armitage trend test (C). TNFα, tumour necrosis factor alpha